Rituximab use and survival after diffuse large B-cell or follicular lymphoma: A population-based study

Theresa H M Keegan, Lisa M. Moy, James M Foran, Ash A. Alizadeh, Ellen T. Chang, Sarah J. Shema, Clayton W. Schupp, Christina A. Clarke, Sally L. Glaser

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

To determine whether reported socioeconomic disparities in survival might be related to treatment, we examined patient and tumor characteristics associated with receipt of rituximab and survival in the National Cancer Institute's Patterns of Care Studies (2003 and 2008) for patients with diffuse large B-cell (DLBCL) and follicular (FL) lymphoma. Patients with DLBCL (n = 1192) were less likely to receive rituximab if they were older, black or Asian, lacked private medical insurance, had impaired performance status, had no lactate dehydrogenase measurements or were diagnosed with stage I disease. Patients with FL (n = 476) were less likely to receive rituximab if they were unmarried or non-Hispanic white. Receipt of rituximab did not differ by neighborhood median income. Treatment with rituximab was associated with better survival for patients with DLBCL, but not patients with FL. Lower rituximab use in patients with DLBCL without private insurance suggests that previously identified socioeconomic disparities in survival may, in part, be explained by receipt of rituximab.

Original languageEnglish (US)
Pages (from-to)743-751
Number of pages9
JournalLeukemia and Lymphoma
Volume54
Issue number4
DOIs
StatePublished - Apr 2013

Fingerprint

Follicular Lymphoma
Lymphoma, Large B-Cell, Diffuse
B-Cell Lymphoma
Survival
Population
B-Lymphocytes
Insurance
National Cancer Institute (U.S.)
Rituximab
L-Lactate Dehydrogenase
Therapeutics

Keywords

  • Diffuse large B-cell lymphoma
  • Disparities
  • Follicular lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Keegan, T. H. M., Moy, L. M., Foran, J. M., Alizadeh, A. A., Chang, E. T., Shema, S. J., ... Glaser, S. L. (2013). Rituximab use and survival after diffuse large B-cell or follicular lymphoma: A population-based study. Leukemia and Lymphoma, 54(4), 743-751. https://doi.org/10.3109/10428194.2012.727415

Rituximab use and survival after diffuse large B-cell or follicular lymphoma : A population-based study. / Keegan, Theresa H M; Moy, Lisa M.; Foran, James M; Alizadeh, Ash A.; Chang, Ellen T.; Shema, Sarah J.; Schupp, Clayton W.; Clarke, Christina A.; Glaser, Sally L.

In: Leukemia and Lymphoma, Vol. 54, No. 4, 04.2013, p. 743-751.

Research output: Contribution to journalArticle

Keegan, THM, Moy, LM, Foran, JM, Alizadeh, AA, Chang, ET, Shema, SJ, Schupp, CW, Clarke, CA & Glaser, SL 2013, 'Rituximab use and survival after diffuse large B-cell or follicular lymphoma: A population-based study', Leukemia and Lymphoma, vol. 54, no. 4, pp. 743-751. https://doi.org/10.3109/10428194.2012.727415
Keegan, Theresa H M ; Moy, Lisa M. ; Foran, James M ; Alizadeh, Ash A. ; Chang, Ellen T. ; Shema, Sarah J. ; Schupp, Clayton W. ; Clarke, Christina A. ; Glaser, Sally L. / Rituximab use and survival after diffuse large B-cell or follicular lymphoma : A population-based study. In: Leukemia and Lymphoma. 2013 ; Vol. 54, No. 4. pp. 743-751.
@article{d89f2f641ce04495bc9349d18a31526d,
title = "Rituximab use and survival after diffuse large B-cell or follicular lymphoma: A population-based study",
abstract = "To determine whether reported socioeconomic disparities in survival might be related to treatment, we examined patient and tumor characteristics associated with receipt of rituximab and survival in the National Cancer Institute's Patterns of Care Studies (2003 and 2008) for patients with diffuse large B-cell (DLBCL) and follicular (FL) lymphoma. Patients with DLBCL (n = 1192) were less likely to receive rituximab if they were older, black or Asian, lacked private medical insurance, had impaired performance status, had no lactate dehydrogenase measurements or were diagnosed with stage I disease. Patients with FL (n = 476) were less likely to receive rituximab if they were unmarried or non-Hispanic white. Receipt of rituximab did not differ by neighborhood median income. Treatment with rituximab was associated with better survival for patients with DLBCL, but not patients with FL. Lower rituximab use in patients with DLBCL without private insurance suggests that previously identified socioeconomic disparities in survival may, in part, be explained by receipt of rituximab.",
keywords = "Diffuse large B-cell lymphoma, Disparities, Follicular lymphoma, Rituximab",
author = "Keegan, {Theresa H M} and Moy, {Lisa M.} and Foran, {James M} and Alizadeh, {Ash A.} and Chang, {Ellen T.} and Shema, {Sarah J.} and Schupp, {Clayton W.} and Clarke, {Christina A.} and Glaser, {Sally L.}",
year = "2013",
month = "4",
doi = "10.3109/10428194.2012.727415",
language = "English (US)",
volume = "54",
pages = "743--751",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Rituximab use and survival after diffuse large B-cell or follicular lymphoma

T2 - A population-based study

AU - Keegan, Theresa H M

AU - Moy, Lisa M.

AU - Foran, James M

AU - Alizadeh, Ash A.

AU - Chang, Ellen T.

AU - Shema, Sarah J.

AU - Schupp, Clayton W.

AU - Clarke, Christina A.

AU - Glaser, Sally L.

PY - 2013/4

Y1 - 2013/4

N2 - To determine whether reported socioeconomic disparities in survival might be related to treatment, we examined patient and tumor characteristics associated with receipt of rituximab and survival in the National Cancer Institute's Patterns of Care Studies (2003 and 2008) for patients with diffuse large B-cell (DLBCL) and follicular (FL) lymphoma. Patients with DLBCL (n = 1192) were less likely to receive rituximab if they were older, black or Asian, lacked private medical insurance, had impaired performance status, had no lactate dehydrogenase measurements or were diagnosed with stage I disease. Patients with FL (n = 476) were less likely to receive rituximab if they were unmarried or non-Hispanic white. Receipt of rituximab did not differ by neighborhood median income. Treatment with rituximab was associated with better survival for patients with DLBCL, but not patients with FL. Lower rituximab use in patients with DLBCL without private insurance suggests that previously identified socioeconomic disparities in survival may, in part, be explained by receipt of rituximab.

AB - To determine whether reported socioeconomic disparities in survival might be related to treatment, we examined patient and tumor characteristics associated with receipt of rituximab and survival in the National Cancer Institute's Patterns of Care Studies (2003 and 2008) for patients with diffuse large B-cell (DLBCL) and follicular (FL) lymphoma. Patients with DLBCL (n = 1192) were less likely to receive rituximab if they were older, black or Asian, lacked private medical insurance, had impaired performance status, had no lactate dehydrogenase measurements or were diagnosed with stage I disease. Patients with FL (n = 476) were less likely to receive rituximab if they were unmarried or non-Hispanic white. Receipt of rituximab did not differ by neighborhood median income. Treatment with rituximab was associated with better survival for patients with DLBCL, but not patients with FL. Lower rituximab use in patients with DLBCL without private insurance suggests that previously identified socioeconomic disparities in survival may, in part, be explained by receipt of rituximab.

KW - Diffuse large B-cell lymphoma

KW - Disparities

KW - Follicular lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=84879538665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879538665&partnerID=8YFLogxK

U2 - 10.3109/10428194.2012.727415

DO - 10.3109/10428194.2012.727415

M3 - Article

C2 - 22957852

AN - SCOPUS:84879538665

VL - 54

SP - 743

EP - 751

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 4

ER -